Hutchingame Growth Capital Corporation v. Dayton Boot Co. Enterprises Ltd, 2019 FCA 152

This Order and Reasons dealt with a motion that was brought by Bayer in the context of a judicial review, which circumstances may be summarized as follows: On August 22, 2023, Bayer made a submission to the Office of Patented Medicines and Liaison (the “OPML”) to list Canadian Patent No. 2,970,315 (the “315 Patent”) on the Patent Register in respect of the product EYLEA®, but the eligibility decision was not made until August 30, 2023;

This Order and Reasons dealt with a motion brought by the plaintiffs (Janssen Inc. and Mitsubishi Tanabe Pharma Corporation, collectively, “Janssen”) for an order requiring the defendant (JAMP Pharma Corporation) to produce certain samples. The motion was brought in the context of an action brought by Janssen under the Patented Medicines (Notice of Compliance) Regulations involving the medicinal ingredient canagliflozin.

Nia Wine Group Co., Ltd. v. North 42 Degrees Estate Winery Inc., 2022 FC 241